{'fraction_non_alphanumeric': 0.03202846975088968, 'fraction_numerical': 0.02491103202846975, 'mean_word_length': 4.702702702702703, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Massive transfusion in cancer surgery. A study of the survival of 21 patients].

In a retrospective study over 5 years, the evolution of 21 patients who received a massive blood transfusion during a carcinological surgery was analyzed. In this type of surgery, the frequency of massive blood transfusion is 0.28% and affects 2.5% of the patients transfused. In half of the cases, surgery was performed to resect an ovarian cancer. The overall death rate, related to the importance of the blood transfusion, is high: 38% (8 patients out of 21). Among the patients who survived (13), the actuarial survival is low: 10 deaths from local or metastatic disease with a mean survival of 12 months, suggesting that the use of massive blood transfusion was related to the tumoral aggressiveness and to the severity of the deepseated malignant disease.